Loading...
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Attard, G Sydes, M Mason, M Clarke, Noel W Aebersold, D de Bono, J Dearnaley, D Parker, C Ritchie, A Russell, J
Attard, G
Sydes, M
Mason, M
Clarke, Noel W
Aebersold, D
de Bono, J
Dearnaley, D
Parker, C
Ritchie, A
Russell, J
Citations
Altmetric:
Abstract
There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.
Affiliation
Description
Date
2014-06-27
Publisher
Collections
Keywords
Type
Article
Citation
Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. 2014: Eur Urol